The prevalence of dislipidemia and its relation to other risk factors: a nationwide survey of Lithuania

Q Medicine

Clinical Lipidology Pub Date : 2015-06-01 DOI:10.2217/clp.15.16

E. Rinkūnienė, A. Laucevičius, Ž. Petrulionienė, V. Dženkevičiūtė, S. Kutkiene, Agnė Skujaitė, V. Kasiulevičius

引用次数: 14

Abstract

Abstract Aim: The aim of this study was to assess the prevalence of dyslipidemia and its relation to other cardiovascular risk factors in Lithuania. Design & methods: The Lithuanian High Cardiovascular Risk Primary Prevention program recruited men and women without overt cardiovascular disease. This report describes the group of 23,204 subjects. Results: Dyslipidemia was diagnosed in 89.7% of subjects. All the main cardiovascular risk factors except for smoking were present more often among patients with dyslipidemia. The average number of risk factors (arterial hypertension, abdominal obesity, diabetes mellitus, metabolic syndrome, smoking, insufficient physical activity, unbalanced diet and family history of CVD) in subjects with dyslipidemia was 3.09 (compared with 2.42 in subjects without it). Conclusion: Dyslipidemia is a most frequent risk factor among middle-aged Lithuanian subjects without cardiovascular disease and has been diagnosed in nine out of ten subjects.

查看原文本刊更多论文

低脂血症的流行及其与其他危险因素的关系:立陶宛全国调查

摘要目的:本研究的目的是评估立陶宛血脂异常的患病率及其与其他心血管危险因素的关系。设计与方法:立陶宛高危心血管初级预防项目招募无明显心血管疾病的男性和女性。这份报告描述了23204名受试者。结果:89.7%的受试者被诊断为血脂异常。除吸烟外，所有主要心血管危险因素在血脂异常患者中更常见。血脂异常组的危险因素(动脉高血压、腹型肥胖、糖尿病、代谢综合征、吸烟、运动不足、饮食不平衡和心血管疾病家族史)平均为3.09个(无血脂异常组为2.42个)。结论:血脂异常是立陶宛无心血管疾病的中年受试者中最常见的危险因素，十分之九的受试者被诊断出患有血脂异常。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lipidology 生物-生化与分子生物学

CiteScore

0.44

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal''s readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as those involved in the treatment of such disorders as diabetes, hypertension, and obesity. The Journal also addresses allied health professionals who treat the patient base described above, such as pharmacists, nurse practitioners and dietitians. Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.